Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation

Informazioni relative al progetto

PanThera

ID dell’accordo di sovvenzione: 101069281

DOI

10.3030/101069281

Progetto chiuso

Data della firma CE 31 Maggio 2022

Data di avvio 1 Ottobre 2022

Data di completamento 31 Marzo 2024

Finanziato da

• European Research Council (ERC)

Costo totale

Nessun dato

Contributo UE

€ 150 000,00

Coordinato da

COLLEGE DE FRANCE
France

Periodic Reporting for period 1 - PanThera (Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation)

Periodo di rendicontazione: 2022-10-01 al 2024-03-31

Sintesi del contesto e degli obiettivi generali del progetto

Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic drugs, one third of epileptic patients are pharmacoresistant and most patients suffer from side effects, making it crucial to develop novel therapies. Current drugs indeed target channels and receptors involved in normal brain function, not specific to the disease.
Our academic work has recently identified a novel and innovative target for epilepsy, which is active during the transition to epileptic seizures. This target could therefore allow to specifically counteract epileptic seizures without altering physiological cerebral processes. Our preclinical investigations have shown that a molecule acting on this target can counteract seizures both ex vivo in human postoperative epileptic tissues and in vivo in an animal model of recurrent focal epilepsy. These results led to a patent for the use of this molecule to treat epileptic conditions. Our project aimed at completing the pharmacological preclinical package of this molecule as an antiepileptic drug.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

To do so, we characterized its pharmacodynamic-pharmacokinetic activity, tested its dose effect in a model of focal epilepsy, as well as assessed its effect on another form on epilepsy.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

This study should contribute to bring to the market a new generation of antiepileptic drugs.